Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sagent Launches Carboplatin Injection | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Sagent Launches Carboplatin Injection

Packaging intended to reduce medication errors

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Sagent Pharmaceuticals has launched Carboplatin Injection, an antineoplastic agent, in four preservative-free vial presentations. The product will be manufactured at Sagent’s SCP facility, a 300,000-sq.-ft. FDA- and cGMP-compliant sterile manufacturing facility located in Chengdu, China. The facility was designed initially to support the supply of chronically short oncology products. Carboplatin is the first product that Sagent will supply from this facility.

Carboplatin Injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. Carboplatin Injection is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.

According to IMS, for the 12 months ending September 2013, the U.S. market for Carboplatin Injection was approximately $30 million. As with all products in Sagent’s portfolio, Carboplatin features Sagent’s PreventIV Measures packaging and labeling, designed to help reduce medication errors.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics